Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Primers Provide Enhanced KRAS Assay Sensitivity

Published: Wednesday, April 10, 2013
Last Updated: Wednesday, April 10, 2013
Bookmark and Share
Swift Biosciences, Inc. has announced the third product in its line of myT® Primer reagents for the detection of cancer mutations.

myT KRAS provides 1% sensitivity for 7 key mutations in codons 12 and 13 with little or no breakthrough amplification from wild-type, resulting in an assay with a definitive Yes/No answer over a wide dynamic range. myT KRAS works well with both fresh frozen and FFPE samples. Each package includes sufficient reagents for 30 samples and is now available directly from Swift.Swift-Biosciences-myT-KRAS.gif

myT Primers have unique structural and thermodynamic properties that enable highly sensitive mismatch discrimination. The selectivity and reproducibility of myT Primers provides an increased level of confidence and convenience in qPCR assays and results in an assay that gives a definitive Yes/No answer over a wide dynamic range, eliminating the need to use a delta Ct method to call a result. myT Primers are ideal for use when the sample material is limiting or where the target is present at very low concentration.  

myT KRAS is the third product in the myT Primer line. myT BRAF, can detect 1% mutant BRAF V600E/K. A second, ultrasensitive version, called myT BRAF-Ultra, provides 0.01% sensitivity down to single copy detection of BRAF V600E/K mutations. Additional myT Primer reagents will be coming soon.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Unravelling the Metastatic Mechanism of Melanoma
Research has uncovered the mechanism of melanoma spreading; the findings could lead to a cure for the disease.
Gene Therapy Via Ultrasound
Research into a gene therapy approach called sonoporation could help combat heart disease and cancer.
Novel MRI Technique Distinguishes Healthy Prostate Tissue from Cancer
The UTSW researchers have determined that glucose stimulates release of the zinc ions from inside epithelial cells, which they could then track on MRIs.
Precision Nanobots Target Cancerous Tumours
Researchers achieve breakthrough toward redefining anti-cancer drug administration using nanorobotics.
PARP Proteins Explore Therapeutic Targets in Cancer
Researchers at UTSW have identified a previously unknown role of a certain class of proteins that opens the door to explore therapeutic targets in cancer and other disease.
Novel Therapeutic Approach for Blood Disorders
Gene editing of human blood-forming stem cells mimics a benign genetic condition that helps to overcome sickle cell disease and other blood disorders.
Immune-Cell Population Predicts Immunotherapy Response in Melanoma
All patients with high levels of one immune-cell type responded to treatment.
Effects of Chemotherapy on Developing Ovaries in Female Fetuses
Researchers at University of Edinburgh have shown that etoposide can damage the development of the ovaries while a fetus is in the womb.
Breast Tumors Evolve in Response to Hormone Therapy
Researchers have suggested that analyzing a single sample of the breast tumor is insufficient for understanding how a patient should best be treated.
Cutting off the Cancer Fuel Supply
Research from investigators at Rutgers Cancer Institute of New Jersey and Princeton University has identified a new approach to cancer therapy in cutting off a cancer cell’s ‘fuel supply’ by targeting a cellular survival mechanism known as autophagy. The co-corresponding authors of the work are Rutgers Cancer Institute Deputy Director Eileen P. White, PhD, and researcher ‘Jessie’ Yanxiang Guo, PhD.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!